New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk] > SAR - DOXOrubicin ARST0332 [intermediate and high risk]
This regimen is a component of SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk]

ARST0332 [intermediate and high risk] - D [DOXOrubicin] (SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk])

Treatment Overview

As cycle 7 (refer Treatment Schema), or as per patient's individual treatment plan.

Cycle 1 - 21 days

Cycle length:
21

DOXOrubicin:

  • Some centres may choose to cap the DOXOrubicin doses to 2 m2 as per ARST0332 i.e. maximum dose of 75 mg per day = 150 mg over 48 hours, OR 
  • Some centres may consider reducing DOXOrubicin dose for certain patients to 20 mg/m2 IV over 15 minutes ONCE daily on days 1 to 3 i.e. total dose of 60 mg/m2 over 3 days.

Cycle details

Cycle 1 - 21 days

Medication Dose Route Days Max Duration
dexamethasone * 8 mg oral administration 1 to 4
ondansetron 8 mg oral administration 1, 2
DOXOrubicin * 37.5 mg/m² Once daily intravenous 1, 2 24 hours Min: 24 hours
ondansetron 8 mg oral administration 1, 2
domperidone 10 mg Three times daily oral administration 1

DOXOrubicin:

  • Some centres may choose to cap the DOXOrubicin doses to 2 m2 as per ARST0332 i.e. maximum dose of 75 mg per day = 150 mg over 48 hours, OR 
  • Some centres may consider reducing DOXOrubicin dose for certain patients to 20 mg/m2 IV over 15 minutes ONCE daily on days 1 to 3 i.e. total dose of 60 mg/m2 over 3 days.

Full details

Cycle 1 - 21 days

Day: 1

Medication Dose Route Max duration Details
dexamethasone * 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy with food.
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy.
DOXOrubicin * 37.5 mg/m² Once daily intravenous 24 hours Min: 24 hours
Instructions:
  • Continuous infusion over 24 hours.
  • Administer daily for 2 days, total dose 75 mg/m2 over 48 hours.
  • Warning vesicant–ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
ondansetron 8 mg oral administration
Instructions:

EIGHT hours after chemotherapy OR before bed.
domperidone 10 mg Three times daily oral administration
Instructions:

When required for nausea and/or vomiting.

The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 2

Medication Dose Route Max duration Details
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy.
DOXOrubicin * 37.5 mg/m² Once daily intravenous 24 hours Min: 24 hours
Instructions:
  • Continuous infusion over 24 hours.
  • Administer daily for 2 days, total dose 75 mg/m2 over 48 hours.
  • Warning vesicant–ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
ondansetron 8 mg oral administration
Instructions:

EIGHT hours after chemotherapy OR before bed.

Day: 3

Medication Dose Route Max duration Details
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.

Day: 4

Medication Dose Route Max duration Details
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.

Supportive Care Factors

Factor Value
Emetogenicity: Medium
Growth factor support: Variable

Growth factor support: May be considered for primary prophylaxis.

References

No references

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.